Clinical trial · Observational
Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm
Value of CD26 Positive Stem Cell Marker in Patients With Classical Myeloproliferative Neoplasms
NCT04312607CI-TRIAL-00044094unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluate diagnostic and prognostic value of CD26 positive stem cell Stem Cells in classic myeloproliferative neoplasms (MPNs). To study CD26 expression on different phases of CML (chronic phase, accelerated phase, blastic phase). To investigate whether CD26 positive stem cell are expressed only in Philadelphia chromosome positive MPN (CML) and/or in Philadelphia chromosome negative MPN (PV, ET, PMF).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloproliferative Neoplasm | Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BCR-ABL gene PCR | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Philadelphia chromosome positive
- description
- according to PCR detection of BCR-ABL gene CD26 expression on stem cells
- interventionNames
- Diagnostic Test: BCR-ABL gene PCR
- label
- Philadelphia chromosome negative
- description
- according to PCR detection of BCR-ABL gene CD26 expression on stem cells
- interventionNames
- Diagnostic Test: BCR-ABL gene PCR
Primary outcomes (1)
- measure
- diagnostic value
- timeFrame
- within 4 months from study start
- description
- diagnostic value of CD 26 in MPNs
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed one of classic MPNs (CML, PV, ET, PMF). Exclusion Criteria: * Patients below 18 years. * Pregnancy. * Any associated Solid or hematopoietic neoplasm.
References
Publications (4)
- BACKGROUNDLevine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007 Sep;7(9):673-83. doi: 10.1038/nrc2210. PMID 17721432
- BACKGROUNDThapa B, Fazal S, Parsi M, Rogers HJ. Myeloproliferative Neoplasms. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK531464/ PMID 30285359
- BACKGROUNDJabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016 Feb;91(2):252-65. doi: 10.1002/ajh.24275. PMID 26799612
- BACKGROUNDRaspadori D, Pacelli P, Sicuranza A, Abruzzese E, Iurlo A, Cattaneo D, Gozzini A, Galimberti S, Barate C, Pregno P, Nicolosi M, Sora F, Annunziata M, Luciano L, Caocci G, Moretti S, Sgherza N, Fozza C, Russo S, Usala E, Liberati MA, Ciofini S, Trawinska MM, Gozzetti A, Bocchia M. Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. Cytometry B Clin Cytom. 2019 Jul;96(4):294-299. doi: 10.1002/cyto.b.21764. Epub 2019 Feb 3. PMID 30714299